

BILL SUMMARY
2nd Session of the 59th Legislature

Bill No.:	SB 1264
Version:	CCR A
Request Number:	
Author:	Rep. Miller
Date:	5/21/2024
Impact:	OMES: Minimal

Research Analysis

Pending

Prepared By: House Research Staff

Fiscal Analysis

SB 1264 requires health benefit plans to provide coverage for clinical genetic testing for inherited gene mutations and evidence-based cancer imaging for individuals with an increased risk of cancer.

Officials from the Oklahoma Health Care Authority (OHCA) do not anticipate this measure to impact Medicaid costs as they currently act in accordance with the recommendations and guidelines of the National Comprehensive Cancer Network (NCCN).

Officials from the Employees Group Insurance Division with the Office of Management and Enterprise Services (OMES-EGID) confirmed HealthChoice currently provides such coverage as recommended by the National Comprehensive Cancer Network (NCCN) clinical practice guidelines. However, the current plan applies member cost share (deductible, coinsurance, copays) where appropriate, which is prohibited by SB 1264. As a result, officials estimate an annual fiscal impact of Six Hundred Thousand Dollars (\$600,000) based on current utilization. Considering the overall total claims spend, OMES confirmed the impact to be minimal and absorbed within the department's current budgetary resources; thus, having minimal impact on the state budget if any.

Prepared By: Alexandra Ladner, House Fiscal Staff

Other Considerations

None.